InvaGen Pharmaceuticals, Inc.

Overview

• HeadquartersNew York, United States²
• Legal formBusiness Corporation²
• LEI549300PSQTOK7P8ZE722²
• StatusActive²
• LEI statusLapsed (not renewed)²
• Registered addressC/O INCORP SERVICES, INC., 12210 Albany, United States²
• Registered withCorporation and Business Entity Database (Division of Corporations, State Records and UCC, Department of State), 2980487²

See how the biggest companies compare on our leaderboards

Corporate structure

InvaGen Pharmaceuticals, Inc. is part of a group headed by Cipla. 13 entities, 4 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries, stakes and holdings from Wikidata (CC0); stakes of 5% or more it reported on Schedules 13D and 13G (1 companies). Each entity in the chart links to its source.

Subsidiaries and ownership

Parent company (GLEIF)

• Cipla²

Ownership links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); each one cites its LEI record.

Timeline

1. Nov 15, 2019Parent Directly consolidated by Cipla²
2. Nov 21, 2003Founded InvaGen Pharmaceuticals, Inc. is founded²

Calendar

Drug trials and FDA: recently

1. Sep 16, 2024FDA approved a new use FDA approved an efficacy supplement for Lanreotide Acetate, a new use or patient group (NDA 215395, supplement 7).³

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Stakes it holds

InvaGen Pharmaceuticals, Inc. has told the SEC it owns more than 5% of 1 company, latest first (Schedules 13D and 13G).

• AVENUE THERAPEUTICS, INC.SC 13D/A Jul 28, 2022 to Oct 19, 2022⁴